Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs FIGS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FIGS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–0 Matrix Metrics)

FIGS Overall Winner 6-Pillar Tally: SKIN 1 – 5 FIGS Matrix Metrics: SKIN 0 – 9 FIGS

As of Nov 16, 2026, FIGS, Inc. (FIGS) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas FIGS carries 43.7/100 (HOLD) at $21.34 (49.2x Forward P/E, 9.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs FIGS
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (315.4% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $12.52 · SMA50: $6.25
FIGS NYSE Head-to-Head Winner
FIGS, Inc.
Apparel & Other Finishd Prods Of Fabrics & Similar Matl
$21.34
-3.22% 1D
Market Cap $3.7B
TTM Revenue $749M
Forward P/E 49.2x
Beta / 30D Vol 1.10β · 59% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 30.0 Fund 35.0 Flow 68.0 Mom 1.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (17.4% over 20 days), RSI 58
RSI-14: 58.4 · SMA20: $21.16 · SMA50: $17.22

6-Pillar Scorecard Institutional Category Breakdown (SKIN 1 – 5 FIGS)

Columns: Metric · SKIN · FIGS
1. Valuation Multiples FIGS
Forward P/E 106.4x 49.2x
Trailing P/E 106.4x 58.0x
PEG Ratio 0.93x N/M
EV / Revenue 0.9x 4.9x
2. Growth & Scale FIGS
Revenue Growth (YoY) -2.1% +25.7%
Earnings Growth (YoY) +0.0% +100.0%
TTM Revenue (USD) $289M $749M
Market Cap $106.3M $3.7B
3. Profitability & Quality FIGS
Gross Margin 67.2% 67.7%
Operating Margin 2.4% 9.7%
Net Profit Margin -6.3% 9.7%
Return on Equity (ROE) -30.1% 16.8%
4. Balance Sheet & Cash Flow FIGS
Cash Generation (TTM) $17M $148M
Cash Flow Margin 5.8% 19.7%
Net Cash / Leverage $161M Net Debt (6.61x D/E) $9.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FIGS
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 517.4% (100th %ile) 77.0% (38th %ile)
Put/Call OI Skew N/A 0.14x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) 58.0% of Rev ($434M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Apparel Manufacturing Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (0) vs FIGS (9)
Institutional Metric SKIN FIGS Criterion Row Edge
Market Capitalization
Scale
$106.3M $3.7B Larger Scale FIGS
Trailing P/E Ratio
Valuation
106.4x 58.0x Lower Multiple FIGS
Forward P/E Ratio
Valuation
106.4x 49.2x Lower Multiple FIGS
Revenue Growth (YoY)
Growth
-2.1% +25.7% Higher Growth FIGS
Operating Margin (TTM)
Profitability
2.4% 9.7% Higher Margin FIGS
Net Profit Margin
Profitability
-6.3% 9.7% Higher Margin FIGS
Return on Equity (ROE)
Capital Efficiency
-30.1% 16.8% Higher ROE FIGS
52-Week Range Position
Momentum
83% ($0–$18) 84% ($9–$24) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 1.10β · 59% Vol Lower Realized Risk FIGS
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 43.7 / 100 (HOLD) Higher Composite FIGS
Trailing 12M Revenue (USD)
Operating Scale
$289M $749M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 67.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) $148M ($9.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +30.91 pp
SKIN: +42.52% · FIGS: +11.61%
3M Horizon SKIN +2357.62 pp
SKIN: +2408.33% · FIGS: +50.71%
6M Horizon SKIN +2299.57 pp
SKIN: +2385.14% · FIGS: +85.57%
1Y Horizon SKIN +930.67 pp
SKIN: +1057.69% · FIGS: +127.02%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SKIN Revenue FIGS Revenue SKIN Op. Margin FIGS Op. Margin Margin Leader
FY2019 $170M $110M 8.1% -0.3% SKIN
FY2020 $120M $260M -14.4% 22.0% FIGS
FY2021 $260M $420M -15.4% 2.6% FIGS
FY2022 $370M $510M -7.1% 7.4% FIGS
FY2023 $400M $550M -32.9% 6.2% FIGS
FY2024 $330M $560M -20.3% 0.4% FIGS
FY2025 $300M $630M -6.9% 6.0% FIGS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FIGS BREAKOUT
22d in phase · OBV NEUTRAL
Current IV 77.0%
IV Percentile 38th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FIGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
FIGS Moat Profile Cyclical / Execution-Driven Positioning
Apparel Manufacturing Operator
Competes within the Apparel Manufacturing value chain with $3.7B market capitalization and 9.7% operating margin.
OpEx & R&D Reinvestment 58.0% of Rev ($434M)
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs FIGS Key Questions & Quantitative Answers

As of Nov 16, 2026, FIGS, Inc. (FIGS) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas FIGS carries 43.7/100 (HOLD) at $21.34 (49.2x Forward P/E, 9.7% operating margin). Technically, SKIN sits in a Markup phase (RSI 69.8, UNCLASSIFIED options structure) and FIGS sits in a Markup phase (RSI 58.4, BREAKOUT options structure).

FIGS leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with FIGS at +25.7% YoY revenue growth and +100.0% YoY earnings growth on $749M TTM revenue (67.7% gross margin, 9.7% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while FIGS shifted +472.7%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 58.0% of Rev ($434M) (0 disclosures) for FIGS.

FIGS screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas FIGS trades at 49.2x Forward P/E, 58.0x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus FIGS (16.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, FIGS carries 77.0% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.10β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.